Some additional supportive data from a longitudinal analysis of the CHAMPION Trial is shown in Figure 12, showing what happened after the many months of experience with PAP-guided therapy in the randomized single-blind phase of the study.^[12]  At that point the clinicians who had been managing their patients with PAP-guided therapy were allowed to continue; however for the first time in a real world setting the clinicians who had been managing the control patients with standard care alone were allowed to begin managing them using the information from their PAP monitoring devices.  The prediction would be that if this works, one would expect the rate of HF hospitalizations in the control patients to fall significantly as they were crossed over from control to active management using PAP guidance, as seen in the next Figure.